Baseline characteristics (N = 36)
| Characteristic . | . |
|---|---|
| Median age, y (range) | 61.6 (47-80) |
| Male sex, n (%) | 22 (61%) |
| White race, n (%) | 35 (97%) |
| Median IgM at screening, mg/dL (range) | 3240 (804-10 300) |
| Median M spike at screening, g/dL (range) | 2.06 (0.63-5.1) |
| Median hemoglobin, g/dL, (range) | 10.7 (8.2-14.5) |
| Median platelet count, n (range) | 242 (74-388) |
| Median beta-2 microglobulin, mg/dL (range) | 3.3 (1.4-7.4) |
| BM involvement, % (range) | 70 (5-100) |
| Lymph nodes and HSM assessment by CT scan, n (%) | |
| Evidence of disease | 29 (81%) |
| ISS-WM at enrollment, n (%) | |
| High risk | 7 (19%) |
| Intermediate risk | 14 (39%) |
| Low risk | 15 (42%) |
| Characteristic . | . |
|---|---|
| Median age, y (range) | 61.6 (47-80) |
| Male sex, n (%) | 22 (61%) |
| White race, n (%) | 35 (97%) |
| Median IgM at screening, mg/dL (range) | 3240 (804-10 300) |
| Median M spike at screening, g/dL (range) | 2.06 (0.63-5.1) |
| Median hemoglobin, g/dL, (range) | 10.7 (8.2-14.5) |
| Median platelet count, n (range) | 242 (74-388) |
| Median beta-2 microglobulin, mg/dL (range) | 3.3 (1.4-7.4) |
| BM involvement, % (range) | 70 (5-100) |
| Lymph nodes and HSM assessment by CT scan, n (%) | |
| Evidence of disease | 29 (81%) |
| ISS-WM at enrollment, n (%) | |
| High risk | 7 (19%) |
| Intermediate risk | 14 (39%) |
| Low risk | 15 (42%) |
HSM indicates hepatosplenomegaly.